The selection pressure of drugs on the AR pathway in PCa is evidenced by the enrichment of AR mutations in the ligand-binding domain (LBD) that broadens its ligand specificity spectrum to low levels of circulating androgens or even non-androgenic therapeutic ligands, reducing clinical treatment effects of PCa and the quality of patient survival [23–27]. Here, AR is linked to posterior cortical atrophy.